Trials / Active Not Recruiting
Active Not RecruitingNCT05910528
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afimkibart | Afimkibart will be administered during the Induction, Maintenance and OLE period. |
Timeline
- Start date
- 2023-07-24
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
- First posted
- 2023-06-18
- Last updated
- 2026-03-24
Locations
11 sites across 4 countries: United States, Belgium, France, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05910528. Inclusion in this directory is not an endorsement.